Cover Image

Nucynta ER/Palexia SR(神經病變性疼痛)- 預測與市場分析

Nucynta ER/Palexia SR (Neuropathic Pain) - Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 302373
出版日期 內容資訊 英文 69 Pages
Back to Top
Nucynta ER/Palexia SR(神經病變性疼痛)- 預測與市場分析 Nucynta ER/Palexia SR (Neuropathic Pain) - Forecast and Market Analysis to 2022
出版日期: 2014年04月30日 內容資訊: 英文 69 Pages




本報告提供神經病變性疼痛(NP)治療藥物──Nucynta ER/Palexia SR之調查分析,彙整疾病概要和治療指南,競爭情形,產品資訊,提供主要國家的銷售額預測等,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 臨床症狀 - 徵兆與症狀
    • 糖尿病疼痛性神經病變
    • 帶狀皰疹後神經痛
    • 三叉神經痛
  • 病因·病理生理學
    • 病因
    • 病理生理學

第4章 疾病的管理

  • 診斷和治療概要
    • 診斷
    • 治療的概要與指南

第5章 競爭評估

  • 概要

第6章 Nucynta ER/Palexia SR

  • 概要
  • 功效
  • 安全性
  • SWOT分析
  • 預測

第7章 附錄


Product Code: GDHC405DFR

Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability. New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile.

Nucynta ER/Palexia SR (tapentadol) is an opioid analgesic that was developed by Grunenthal in conjunction with Johnson & Johnson (J&J), first as an immediate-release formulation indicated for acute pain, and later as an ER formulation for the management of chronic pain. Tapentadol has a dual mechanism of action as an agonist of the µ-opioid receptor and as a norepinephrine reuptake inhibitor, and was developed as an improvement to tramadol, which has weak opioid activity, but also inhibits the reuptake of both serotonin and norepinephrine (Tzschentke et al., 2007).


  • Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Nucynta ER/Palexia SR including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Nucynta ER/Palexia SR for the top six countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain and the UK.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Neuropathic pain
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Nucynta ER/Palexia SR performance
  • Obtain sales forecast for Nucynta ER/Palexia SR from 2012-2022 in the top six countries (the US, France, Germany, Italy, Spain and the UK).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Clinical Manifestations of Neuropathic Pain - Signs and Symptoms
    • 3.1.1. Painful Diabetic Neuropathy
    • 3.1.2. Postherpetic Neuralgia
    • 3.1.3. Trigeminal Neuralgia
  • 3.2. Etiology and Pathophysiology
    • 3.2.1. Etiology
    • 3.2.2. Pathophysiology

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Overview and Guidelines

5. Competitive Assessment

  • 5.1. Overview

6. Nucynta ER/Palexia SR

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed PDN, PHN, and TN Patients
    • 7.4.2. Percent Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Physicians and Specialists Included in This Study
  • 7.6. About the Authors
    • 7.6.1. Author
    • 7.6.2. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Classification of NP Syndromes Based on the Site of Somatosensory Damage
  • Table 2: Signs and Symptoms of NP
  • Table 3: Screening Tools for NP
  • Table 4: NP-Related Signs and Symptoms
  • Table 5: Treatment Guidelines for NP
  • Table 6: Recommended Drug Therapies for NP Conditions by Line of Therapy
  • Table 7: Most Prescribed Drugs for NP by Indication and Line of Therapy in the Global Markets, 2012
  • Table 8: NNT and NNH for Classes of Oral Drugs used in NP Treatment, 2013
  • Table 9: Select Products Used for NP Treatment, 2013
  • Table 10: Product Profile - Nucynta ER/Palexia SR
  • Table 11: Nucynta ER/Palexia SR SWOT Analysis, 2013
  • Table 12: Global Sales Forecasts ($m) for Nucynta ER/Palexia SR, 2012-2022

List of Figures

  • Figure 1: Nociceptive Versus Neuropathic Pain
  • Figure 2: Etiology and Pathophysiology of NP
  • Figure 3: Pain Pathway - Somatosensory System
  • Figure 4: Pathophysiological Mechanisms of NP at Different Levels of the Nervous System
  • Figure 5: Pathophysiological Targets of NP Drugs
  • Figure 6: NeuSPIG Diagnostic Certainty Algorithm for NP
  • Figure 7: General Treatment Algorithm for NP
Back to Top